English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objectives  To determine the contribution of peripheral blood mononuclear cells’ (PBMCs) HIV DNA levels to HIV-associated dementia (HAD) and non-demented HIV-associated neurocognitive disorders (HAND) in chronically HIV-infected adults with long-term viral suppression on combined antiretroviral treatment (cART).    Methods  Eighty adults with chronic HIV infection on cART (>97% with plasma and CSF HIV RNA <50 copies/mL) were enrolled into a prospective observational cohort and underwent assessments of neurocognition and pre-morbid cognitive ability at two visits 18 months apart. HIV DNA in PBMCs was measured by real-time PCR at the same time-points.    Results  At baseline, 46% had non-demented HAND; 7.5% had HAD. Neurocognitive decline occurred in 14% and was more likely in those with HAD ( p <.03). Low pre-morbid cognitive ability was uniquely associated with HAD ( p <.05). Log 10  HIV DNA copies were stable between study visits (2.26 vs. 2.22 per 10 6  PBMC). Baseline HIV DNA levels were  higher  in those with  lower  pre-morbid cognitive ability ( p <.04), and  higher  in those with no ART treatment during HIV infection 1st year ( p  = .03). Baseline HIV DNA was not associated with overall neurocognition. However, %  ln  HIV DNA change was associated with decline in semantic fluency in unadjusted and adjusted analyses ( p  = .01-.03), and motor-coordination ( p  = .02-.12) to a lesser extent.    Conclusions  PBMC HIV DNA plays a role in HAD pathogenesis, and this is moderated by pre-morbid cognitive ability in the context of long-term viral suppression. While the HIV DNA levels in PBMC are not associated with current non-demented HAND, increasing HIV DNA levels were associated with a decline in neurocognitive functions associated with HAND progression.

Peripheral Blood Mononuclear Cells HIV DNA Levels Impact Intermittently on Neurocognition